Multiple myelomahematopoietic stem cell transplantationMultiple myeloma is a malignant clonal plasma cell disorder that accounts for about 10% of all hematological malignancies. Conventional melphalan-based chemotherapy produces less than 5% of complete remission rates, with less than 5% of patients ...
Homeopathic Treatment for Multiple MyelomaMultiple Myeloma is a malignant or cancerous condition of the plasma cells of the blood. It is also called Plasma cell Myeloma. The word Myeloma pertains to the cells of bone marrow. The bone marrow is a soft substance within the bones that manufactures...
In spite of its reputation as a chemosensitive malignancy, multiple myeloma remains fatal for nearly all those who contract it. The mortality has changed little in the last 30 years (Feinleib & MacMahon, 1960), although the duration of the illness has been extended from a median of 7 ...
The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
For multiple myeloma, the target for bispecifics is the B cell maturation antigen (BCMA). Notably, teclistamab (Tecvayli; Janssen Biotech, Inc)—which was approved by the FDA about 2 years ago—quickly joined the armamentarium because of its efficiency and its efficacy in patients who ...
Hematopoietic stem cell transplantation is not suitable for patients more than 70 years old. ⑴ Autologous hematopoietic stem cell transplantation: it is a great step of multiple myeloma treatment progress. Its treatment effect is obviously better than that of conventional chemotherapy. Moreover, the...
The development of bortezomib (Velcade) as a treatment for multiple myeloma and mantle cell lymphoma has verified this and suggests that targeting other ... P D’Arcy,S Linder - 《International Journal of Biochemistry & Cell Biology》 被引量: 159发表: 2012年 Identifying candidate allogeneic NK-...
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma Current treatment strategies for multiple myeloma (MM) are highly effective, but most patients develop relapsed/refractory disease (RRMM). The anti-CD38/CD... AL Gr...
Annals of Hematology (2022) 101:1031–1038 https://doi.org/10.1007/s00277-022-04775-1 ORIGINAL ARTICLE Therapy‑related myeloid neoplasms following treatment for multiple myeloma—a single center analysis A. Boquoi1 · S. M. Banahan1 · A. Mohring1 · I. Savic...
4. Kumar SK, Jacobus SJ, Cohen AD, et al: Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomised, ...